You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company is also working in parallel on an at-home test that would be over the counter and return results within an hour.
The program uses an informatics system that converts genotype results to "traffic lights" telling clinicians whether a drug is acceptable for a certain patient.
The firm's new application of its BCR-ABL test will be able to detect p190 transcripts and is currently for research use only.
The firm has a molecular SARS-CoV-2 test in development on its Revogene platform and will be distributing an antigen test.
The company is currently working on multiple infectious disease products, including a panel for sexually transmitted infections and one for SARS-CoV-2.
The international competition's goal is to spark innovation and accelerate safe returns to work, school, and other public activities.
The company, which went public in June, has had to deal with issues with the US DOJ, and some private insurers. Its CEO's tenure at Sequenom was also marred by a scandal.
The company's RaPID platform detects infections directly from a blood sample and can provide results in three hours.
On a conference call to discuss the company's third quarter financial results, executives said they increased molecular test production by 50 percent during the quarter.
New offerings from the oncology testing company include Inivita's InvisionFirst-Lung test and the NeoLab solid tumor test.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.